Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF K601N||lung non-small cell carcinoma||no benefit||Vemurafenib||Case Reports/Case Series||Actionable||In a Phase II trial, Zelboraf (vemurafenib) treatment did not result in response in the cohort of 15 non-small cell lung cancer patients with non-V600 BRAF mutations, which included 2 patients harboring BRAF K601N, and enrollment in this cohort was discontinued (PMID: 31959346; NCT02304809).||31959346|
|BRAF K601N||hematologic cancer||sensitive||LY3009120||LY3009120||Preclinical - Cell culture||Actionable||In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).||26732095|
|BRAF K601N||Advanced Solid Tumor||resistant||Vemurafenib||Preclinical - Cell culture||Actionable||In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).||26343582|